| Properties | Information |
|---|---|
| PhytoCAT-ID | PhytoCAT-1608 |
| Phytochemical name or plant extracts | Hydroxyl safflower yellow B (HSYB) |
| PMID | 33850567 |
| Literature evidence | Doxorubicin (DOX) is currently the preferred chemotherapeutic agent for breast cancer, and hydroxyl safflower yellow B (HSYB) has a tumor growth-inhibiting activity. |
| IUPAC name | NA |
| Phytochemicals’ class or type of plant extracts | NA |
| Source of phytochemicals or plant Extracts | NA |
| Geographical availability | NA |
| Plant parts | NA |
| Other cancers | Breast cancer |
| Target gene or protein | Caspase 9, Bax, Caspase 3 |
| Gene or Protein evidence | Combined HSYB and DOX treatment significantly decreased the expression levels of BCL-2 in MCF-7 cells, while the expression levels of apoptosis-associated proteins, including cleaved caspase-9, BAX and cleaved caspase-3, were markedly increased. |
| Target pathways | NA |
| IC50 | NA |
| Potency | Furthermore, flow cytometry and western blot analysis demonstrated that combined HSYB and DOX treatment stimulated an increase in intracellular reactive oxygen species and promoted the release of cytochrome c, leading to apoptosis. |
| Cell line/ mice model | MCF-7 |
| Additional information | The current data suggested that the combination of HSYB and DOX may have marked antitumor activity. |
| PubChem ID | NA |
| Additional PMIDs | NA |
| Additional sources of information | NA |
| Safety | NA |